Olaratumab and doxorubicin versus doxorubicin alone in soft tissue sarcoma

BACKGROUND: Median overall survival for patients with metastatic soft tissue sarcoma is 12 to 16 months. Olaratumab is a human anti–platelet-derived growth factor receptor α monoclonal antibody which has antitumour activity in human sarcoma xenografts. METHODS: We conducted an open-label phase 1b, r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet
Main Authors: Tap, William D., Jones, Robin L., Van Tine, Brian A., Chmielowski, Bartosz, Elias, Anthony D., Adkins, Douglas, Agulnik, Mark, Cooney, Matthew M., Livingston, Michael B., Pennock, Gregory, Hameed, Meera R., Shah, Gaurav D., Qin, Amy, Shahir, Ashwin, Cronier, Damien M., Ilaria, Robert, Conti, Ilaria, Cosaert, Jan, Schwartz, Gary K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5647653/
https://ncbi.nlm.nih.gov/pubmed/27291997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(16)30587-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados